Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas
Brief Summary: RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.

PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with B-cell leukemia or lymphoma that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to chemotherapy.


Options:
A: Arm Label: Treatment (genetically modified T cell infusion); Type: EXPERIMENTAL; Interventions: Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, Procedure: autologous hematopoietic stem cell transplantation, Other: laboratory biomarker analysis | Intervention Type: BIOLOGICAL; Name: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; Assigned to Arm(s): Treatment (genetically modified T cell infusion) | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Treatment (genetically modified T cell infusion) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Treatment (genetically modified T cell infusion)
B: Arm Label: Phase 1 - Cohort 1A; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 1 - Cohort 1B; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 1 - Cohort 1C; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 1 - Cohort 1D; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 1 - Cohort 1F1; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 1 - Cohort 1F2; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 2; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Intervention Type: BIOLOGICAL; Name: Patient Derived CD19 specific CAR T cells also expressing an EGFRt; Assigned to Arm(s): Phase 1 - Cohort 1A, Phase 1 - Cohort 1B, Phase 1 - Cohort 1C, Phase 1 - Cohort 1D, Phase 1 - Cohort 1F1, Phase 1 - Cohort 1F2, Phase 2
C: Arm Label: HIGH DOSE CHEMOTHERAPY AND ASCT; Type: EXPERIMENTAL; Interventions: Drug: Carmustine, Drug: Etoposide, Drug: Cytarabine, Drug: Melphalan, Biological: Pegfilgrastim, Biological: 19-28z T CELLS, Procedure: Autologous Stem Cell Transplantation | Intervention Type: DRUG; Name: Carmustine; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: BIOLOGICAL; Name: Pegfilgrastim; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: BIOLOGICAL; Name: 19-28z T CELLS; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: PROCEDURE; Name: Autologous Stem Cell Transplantation; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT
D: Arm Label: anti-CD19/20 CAR T cells; Type: EXPERIMENTAL; Interventions: Biological: anti-CD19/20-CAR vector-transduced T cells | Intervention Type: BIOLOGICAL; Name: anti-CD19/20-CAR vector-transduced T cells; Assigned to Arm(s): anti-CD19/20 CAR T cells

Answer: D